JP6567425B2 - Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着 - Google Patents

Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着 Download PDF

Info

Publication number
JP6567425B2
JP6567425B2 JP2015556506A JP2015556506A JP6567425B2 JP 6567425 B2 JP6567425 B2 JP 6567425B2 JP 2015556506 A JP2015556506 A JP 2015556506A JP 2015556506 A JP2015556506 A JP 2015556506A JP 6567425 B2 JP6567425 B2 JP 6567425B2
Authority
JP
Japan
Prior art keywords
cells
cell
endothelial
amg
blinatumomab
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2015556506A
Other languages
English (en)
Japanese (ja)
Other versions
JP2016514090A (ja
Inventor
ペーター クファー
ペーター クファー
マティアス クリンガー
マティアス クリンガー
パトリック ホフマン
パトリック ホフマン
ヴィルギニー ネーゲレ
ヴィルギニー ネーゲレ
エレーヌ−パシュパティ ドプファー
エレーヌ−パシュパティ ドプファー
ディルク ナゴルゼン
ディルク ナゴルゼン
ユルゲン シェーレ
ユルゲン シェーレ
ゲアハルト ツグマイヤー
ゲアハルト ツグマイヤー
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amgen Research Munich GmbH
Original Assignee
Amgen Research Munich GmbH
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amgen Research Munich GmbH filed Critical Amgen Research Munich GmbH
Publication of JP2016514090A publication Critical patent/JP2016514090A/ja
Priority to JP2019098999A priority Critical patent/JP6933684B2/ja
Application granted granted Critical
Publication of JP6567425B2 publication Critical patent/JP6567425B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/095—Sulfur, selenium, or tellurium compounds, e.g. thiols
    • A61K31/10—Sulfides; Sulfoxides; Sulfones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/65—Tetracyclines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
    • A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/04—Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A)

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biochemistry (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Toxicology (AREA)
  • Dermatology (AREA)
  • Cell Biology (AREA)
  • Endocrinology (AREA)
  • Biotechnology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
JP2015556506A 2013-02-08 2014-02-07 Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着 Active JP6567425B2 (ja)

Priority Applications (1)

Application Number Priority Date Filing Date Title
JP2019098999A JP6933684B2 (ja) 2013-02-08 2019-05-28 Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201361762718P 2013-02-08 2013-02-08
US61/762,718 2013-02-08
US201361811526P 2013-04-12 2013-04-12
US61/811,526 2013-04-12
PCT/EP2014/052406 WO2014122251A2 (en) 2013-02-08 2014-02-07 Anti-leukocyte adhesion for the mitigation of potential adverse events caused by cd3-specific binding domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2019098999A Division JP6933684B2 (ja) 2013-02-08 2019-05-28 Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着

Publications (2)

Publication Number Publication Date
JP2016514090A JP2016514090A (ja) 2016-05-19
JP6567425B2 true JP6567425B2 (ja) 2019-08-28

Family

ID=50231117

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2015556506A Active JP6567425B2 (ja) 2013-02-08 2014-02-07 Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着
JP2019098999A Active JP6933684B2 (ja) 2013-02-08 2019-05-28 Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2019098999A Active JP6933684B2 (ja) 2013-02-08 2019-05-28 Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着

Country Status (12)

Country Link
US (2) US9688760B2 (enExample)
EP (2) EP2953630B1 (enExample)
JP (2) JP6567425B2 (enExample)
AR (1) AR094740A1 (enExample)
AU (2) AU2014214020B2 (enExample)
CA (1) CA2898032C (enExample)
ES (1) ES2811764T3 (enExample)
JO (1) JO3529B1 (enExample)
MX (2) MX368842B (enExample)
TW (2) TWI704920B (enExample)
UY (1) UY35313A (enExample)
WO (1) WO2014122251A2 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019178142A (ja) * 2013-02-08 2019-10-17 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2701741B1 (en) * 2011-04-28 2020-06-10 Amgen Research (Munich) GmbH Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
EP2747781B1 (en) 2011-08-23 2017-11-15 Roche Glycart AG Bispecific antibodies specific for t-cell activating antigens and a tumor antigen and methods of use
WO2014056783A1 (en) 2012-10-08 2014-04-17 Roche Glycart Ag Fc-free antibodies comprising two fab-fragments and methods of use
EP4282419A1 (en) 2012-12-20 2023-11-29 Purdue Research Foundation Chimeric antigen receptor-expressing t cells as anti-cancer therapeutics
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JP6499087B2 (ja) 2013-02-26 2019-04-10 ロシュ グリクアート アーゲー 二重特異性ｔ細胞活性化抗原結合分子
WO2014131712A1 (en) 2013-02-26 2014-09-04 Roche Glycart Ag Bispecific t cell activating antigen binding molecules
US10101247B2 (en) * 2013-07-19 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
MX379030B (es) 2013-12-17 2025-03-10 Genentech Inc Anticuerpos anti-cd3 y metodos de uso
FI3531133T3 (fi) 2014-05-30 2023-11-02 Amgen Res Munich Gmbh Prekursori-b-solujen akuutin lymfoblastisen leukemian potilaiden riskiluokittelu
RS65573B1 (sr) 2014-08-04 2024-06-28 Hoffmann La Roche Bispecifični antigen vezujući molekuli koji aktiviraju t ćelije
MA40579A (fr) 2014-09-12 2016-03-17 Genentech Inc Anticorps anti-cll-1 et immunoconjugués
BR112017010513A2 (pt) 2014-11-20 2018-04-03 F. Hoffmann-La Roche Ag ?cadeias leves comuns e métodos de uso?
FI4141032T3 (fi) 2014-11-20 2024-07-31 Hoffmann La Roche T-solua aktivoivien bispesifisten antigeeniä sitovien molekyylien ja pd-1-akselia sitovien antagonistien yhdistelmähoito
EP3221356B1 (en) 2014-11-20 2020-09-02 F.Hoffmann-La Roche Ag T cell activating bispecific antigen binding molecules against folr1 and cd3
HRP20231134T1 (hr) 2015-06-16 2024-01-05 F. Hoffmann - La Roche Ag Humanizirana i afinitetno zrela protutijela na fcrh5 i postupci za uporabu
CN107847568B (zh) 2015-06-16 2022-12-20 豪夫迈·罗氏有限公司 抗cll-1抗体和使用方法
WO2017040324A1 (en) * 2015-08-28 2017-03-09 The Trustees Of The University Of Pennsylvania Methods and compositions for cells expressing a chimeric intracellular signaling molecule
CN106554414B (zh) * 2015-09-18 2019-04-23 上海科济制药有限公司 抗cd19全人抗体以及靶向cd19的免疫效应细胞
AR106188A1 (es) 2015-10-01 2017-12-20 Hoffmann La Roche Anticuerpos anti-cd19 humano humanizados y métodos de utilización
KR20180073561A (ko) 2015-10-02 2018-07-02 에프. 호프만-라 로슈 아게 이중특이적 항-ceaxcd3 t 세포 활성화 항원 결합 분자
US10101248B1 (en) * 2015-12-02 2018-10-16 Rarecyte, Inc. Solution and method for adhering suspension components to a substrate
AU2016368469B2 (en) 2015-12-09 2023-11-02 F. Hoffmann-La Roche Ag Type II anti-CD20 antibody for reducing formation of anti-drug antibodies
AR107303A1 (es) 2016-01-08 2018-04-18 Hoffmann La Roche Métodos de tratamiento de cánceres positivos para ace utilizando antagonistas de unión a eje pd-1 y anticuerpos biespecíficos anti-ace / anti-cd3, uso, composición, kit
LT3433280T (lt) 2016-03-22 2023-07-10 F. Hoffmann-La Roche Ag Proteazės aktyvuojamos t ląstelei bispecifinės molekulės
US12144850B2 (en) 2016-04-08 2024-11-19 Purdue Research Foundation Methods and compositions for car T cell therapy
JP6225321B1 (ja) * 2016-08-31 2017-11-08 王子ホールディングス株式会社 ポリ硫酸ペントサンの製造方法
EP3677587A4 (en) 2016-08-31 2021-04-14 Oji Holdings Corporation XYLOOLIGOSACCHARIDE ACID, AND METHOD FOR MANUFACTURING THE SAME
US10882918B2 (en) 2016-09-30 2021-01-05 Hoffmann-La Roche Inc. Bispecific T cell activating antigen binding molecules
KR20190074300A (ko) 2016-11-15 2019-06-27 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체에 의한 치료를 위한 투약
AU2018219226B2 (en) 2017-02-07 2024-12-19 Seattle Children's Hospital (dba Seattle Children's Research Institute) Phospholipid ether (PLE) CAR T cell tumor targeting (CTCT) agents
JP6281659B1 (ja) 2017-02-28 2018-02-21 王子ホールディングス株式会社 ポリ硫酸ペントサン、医薬組成物及び抗凝固剤
ES3010559T3 (en) 2017-02-28 2025-04-03 Endocyte Inc Compositions and methods for car t cell therapy
US11344578B2 (en) 2017-04-19 2022-05-31 Board Of Regents, The University Of Texas System Immune cells expressing engineered antigen receptors
CA3065747C (en) 2017-05-31 2024-10-01 Oji Holdings Corporation MOISTURIZING COMPOSITION CONTAINING PENTOSANNE POLYSULFATE
AU2018333249B2 (en) 2017-09-12 2023-03-02 Oji Holdings Corporation Pentosan polysulfate and method for producing pentosan polysulfate
CN111148533A (zh) 2017-09-19 2020-05-12 麻省理工学院 用于嵌合抗原受体t细胞疗法的组合物及其用途
WO2019124363A1 (ja) 2017-12-20 2019-06-27 王子ホールディングス株式会社 ポリ硫酸ペントサン及びポリ硫酸ペントサンを含む医薬
US11311576B2 (en) 2018-01-22 2022-04-26 Seattle Children's Hospital Methods of use for CAR T cells
WO2019156795A1 (en) 2018-02-06 2019-08-15 Seattle Children's Hospital (dba Seattle Children's Research Institute) Fluorescein-specific cars exhibiting optimal t cell function against fl-ple labelled tumors
AR115360A1 (es) 2018-02-08 2021-01-13 Genentech Inc Moléculas de unión al antígeno y métodos de uso
WO2019165121A1 (en) 2018-02-21 2019-08-29 Board Of Regents, The University Of Texas System Methods for activation and expansion of natural killer cells and uses therof
CA3091674A1 (en) 2018-02-23 2019-08-29 Endocyte, Inc. Sequencing method for car t cell therapy
AU2019346335B2 (en) 2018-09-28 2024-07-25 Massachusetts Institute Of Technology Collagen-localized immunomodulatory molecules and methods thereof
EP3962948A1 (en) * 2019-04-30 2022-03-09 Amgen Research (Munich) GmbH Means and methods of treating burkitt lymphoma or leukemia
BR112021022682A2 (pt) 2019-05-14 2022-02-22 Provention Bio Inc Métodos e composições para prevenir diabetes do tipo 1
US11642409B2 (en) 2019-06-26 2023-05-09 Massachusetts Insttute of Technology Immunomodulatory fusion protein-metal hydroxide complexes and methods thereof
WO2021061648A1 (en) 2019-09-23 2021-04-01 Massachusetts Institute Of Technology Methods and compositions for stimulation of endogenous t cell responses
BR112022011357A2 (pt) 2019-12-13 2022-08-23 Genentech Inc Anticorpos isolado, um ou mais ácidos nucleicos isolados, um ou mais vetores, uma ou mais células hospedeiras, composição, kit, uso do anticorpo, métodos para produzir o anticorpo e método para tratar ou retardar a progressão de um câncer ly6g6d positivo
KR20220163940A (ko) 2020-02-04 2022-12-12 시애틀 칠드런즈 호스피탈 디/비/에이 시애틀 칠드런즈 리서치 인스티튜트 항-디니트로페놀 키메라 항원 수용체
US11896619B2 (en) 2020-03-10 2024-02-13 Massachusetts Institute Of Technology Compositions and methods for immunotherapy of NPM1c-positive cancer
CA3173527A1 (en) 2020-03-10 2021-09-16 Massachusetts Institute Of Technology Methods for generating engineered memory-like nk cells and compositions thereof
CA3171235A1 (en) * 2020-03-12 2021-09-16 Sydney David Cullis-Hill Treatment for coronavirus infection and associated cytokine toxicity
WO2021221782A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Chimeric antigen receptor-targeting ligands and uses thereof
WO2021221783A1 (en) 2020-05-01 2021-11-04 Massachusetts Institute Of Technology Methods for identifying chimeric antigen receptor-targeting ligands and uses thereof
US12006366B2 (en) 2020-06-11 2024-06-11 Provention Bio, Inc. Methods and compositions for preventing type 1 diabetes
TWI852680B (zh) 2020-06-19 2024-08-11 瑞士商赫孚孟拉羅股份公司 與 cd3 及 cd19 結合之抗體
WO2022060901A1 (en) * 2020-09-16 2022-03-24 Amgen Inc. Methods for administering therapeutic doses of bispecific t-cell engaging molecules for the treatment of cancer
TWI874719B (zh) 2020-11-04 2025-03-01 美商建南德克公司 用抗cd20/抗cd3雙特異性抗體進行治療之給藥
AU2021374590A1 (en) 2020-11-04 2023-06-01 Genentech, Inc. Subcutaneous dosing of anti-cd20/anti-cd3 bispecific antibodies
KR20230095113A (ko) 2020-11-04 2023-06-28 제넨테크, 인크. 항-cd20/항-cd3 이중특이적 항체들과 항-cd79b 항체 약물 접합체들을 이용한 치료를 위한 투약
CN112521513B (zh) * 2020-12-15 2021-08-24 青岛西凯生物技术有限公司 一种靶向cd19的嵌合抗原受体(car)及其应用
WO2022228705A1 (en) 2021-04-30 2022-11-03 F. Hoffmann-La Roche Ag Dosing for combination treatment with anti-cd20/anti-cd3 bispecific antibody and anti-cd79b antibody drug conjugate
KR20240007171A (ko) 2021-05-14 2024-01-16 제넨테크, 인크. 모수네투주맙 및 폴라투주맙 베도틴을 이용한 cd20 양성 증식성 장애의 치료 방법
WO2022251253A1 (en) 2021-05-24 2022-12-01 Provention Bio, Inc. Methods for treating type 1 diabetes
CN113637087A (zh) * 2021-07-09 2021-11-12 上海易慕峰生物科技有限公司 一种提高细胞免疫疗法安全性的嵌合受体和细胞
US20260083848A1 (en) 2021-11-03 2026-03-26 Viracta Therapeutics, Inc. Combination of car t-cell therapy with btk inhibitors and methods of use thereof
WO2024206166A1 (en) * 2023-03-31 2024-10-03 Memorial Sloan-Kettering Cancer Center Microenvironment actuated t-cells and uses thereof

Family Cites Families (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2689848A (en) 1951-02-06 1954-09-21 Wander Ag Dr A Salts of sulfuric acid esters of xylan
AU612370B2 (en) 1987-05-21 1991-07-11 Micromet Ag Targeted multifunctional proteins
US5605938A (en) 1991-05-31 1997-02-25 Gliatech, Inc. Methods and compositions for inhibition of cell invasion and fibrosis using dextran sulfate
AU687755B2 (en) * 1992-08-21 1998-03-05 Genentech Inc. Method for treating an LFA-1-mediated disorder
KR100508289B1 (ko) 1998-04-21 2005-08-17 마이크로메트 에이지 Ｃｄ１９×ｃｄ３ 특이 폴리펩티드 및 그의 용도
AU2004242846A1 (en) 2003-05-31 2004-12-09 Micromet Ag Pharmaceutical compositions comprising bispecific anti-CD3, anti-CD19 antibody constructs for the treatment of B-cell related disorders
CA2478458A1 (en) * 2004-08-20 2006-02-20 Michael Panzara Treatment of pediatric multiple sclerosis
SI1976886T1 (sl) 2005-12-16 2015-03-31 Amgen Research (Munich) Gmbh Sredstva in postopki za zdravljenje tumorskih bolezni
AU2007248019B2 (en) 2006-05-03 2012-10-11 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Chimeric T cell receptors and related materials and methods of use
MX2008015771A (es) * 2006-06-14 2009-01-27 Macrogenics Inc Metodos para el tratamiento de padecimientos autoinmunes usando anticuerpos monoclonales con toxicidad reducida.
WO2008107906A1 (en) 2007-03-06 2008-09-12 Alembic Limited Process for the preparation of pentosan polysulfate or salts thereof
SG10201808730VA (en) * 2007-04-03 2018-11-29 Amgen Res Munich Gmbh Cross-species-specific binding domain
CN109456410B (zh) 2007-04-03 2022-01-28 安进研发（慕尼黑）股份有限公司 跨物种特异性CD3-ε结合结构域
US20100183615A1 (en) 2007-04-03 2010-07-22 Micromet Ag Cross-species-specific bispecific binders
EA201000219A1 (ru) * 2007-07-17 2010-12-30 Комбинейторкс, Инкорпорейтед Способ и композиция для лечения в-клеточных пролиферативных нарушений
WO2009011897A1 (en) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Combinations for the treatment of b-cell proliferative disorders
EP2188281A1 (en) 2007-08-10 2010-05-26 Y's Therapeutics Co, Ltd. Modulation of immune responses by administration of roxithromycin or its derivative
US8026343B2 (en) * 2008-08-08 2011-09-27 Dinona Inc. Antibody modulating the differentiation and function of dendritic cells via binding intercellular adhesion molecule-1 and use thereof
EP4180458A1 (en) * 2008-10-01 2023-05-17 Amgen Research (Munich) GmbH Cross-species-specific psma x cd3 bispecific single chain antibody
BR112012009778A2 (pt) * 2009-10-27 2017-06-13 Micromet Ag regime de dosagem para administrar um anticorpo biespecífico de cd19xcd3
KR101889995B1 (ko) * 2010-10-27 2018-08-20 암젠 리서치 (뮌헨) 게엠베하 Dlbcl의 치료 수단 및 방법
SMT201700250T1 (it) * 2010-11-10 2017-07-18 Amgen Res Munich Gmbh Prevenzione di effetti avversi provocati da domini leganti cd3 specifici
US9402865B2 (en) * 2011-01-18 2016-08-02 The Trustees Of The University Of Pennsylvania Compositions and methods for treating cancer
EP2701741B1 (en) * 2011-04-28 2020-06-10 Amgen Research (Munich) GmbH Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
US9682143B2 (en) * 2012-08-14 2017-06-20 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
CN102875685B (zh) 2012-09-29 2013-12-25 郑骏年 嵌合抗原受体hFⅦL-CD8-OX40-CD3ζ及其用途
US9486475B2 (en) * 2013-02-08 2016-11-08 Amgen Research (Munich) Gmbh PPS for the prevention of potential adverse effects caused by CD3 specific binding domains
JO3529B1 (ar) * 2013-02-08 2020-07-05 Amgen Res Munich Gmbh مضاد التصاق خلايا الدم البيض من أجل التخفيف من الاثار السلبية الممكنة الناتجة عن مجالات ارتباط cd3- المحدد

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2019178142A (ja) * 2013-02-08 2019-10-17 アムゲン リサーチ （ミュンヘン） ゲーエムベーハーＡＭＧＥＮ Ｒｅｓｅａｒｃｈ（Ｍｕｎｉｃｈ）ＧｍｂＨ Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着

Also Published As

Publication number Publication date
CA2898032C (en) 2021-06-15
US20140227272A1 (en) 2014-08-14
MX368842B (es) 2019-10-18
MX2019012421A (es) 2022-10-13
JP2016514090A (ja) 2016-05-19
ES2811764T3 (es) 2021-03-15
UY35313A (es) 2014-08-29
WO2014122251A3 (en) 2014-10-02
CA2898032A1 (en) 2014-08-14
EP2953630B1 (en) 2020-07-01
TW201929865A (zh) 2019-08-01
AU2014214020B2 (en) 2018-11-15
WO2014122251A2 (en) 2014-08-14
AU2019200841B2 (en) 2020-08-13
EP2953630A2 (en) 2015-12-16
AU2014214020A1 (en) 2015-07-30
HK1216996A1 (zh) 2016-12-16
TWI704920B (zh) 2020-09-21
US9688760B2 (en) 2017-06-27
JP6933684B2 (ja) 2021-09-08
MX2015009922A (es) 2015-09-25
TW201442714A (zh) 2014-11-16
JP2019178142A (ja) 2019-10-17
EP3760210A1 (en) 2021-01-06
AU2019200841A1 (en) 2019-02-28
US20170327581A1 (en) 2017-11-16
AR094740A1 (es) 2015-08-26
US11084876B2 (en) 2021-08-10
JO3529B1 (ar) 2020-07-05

Similar Documents

Publication Publication Date Title
JP6933684B2 (ja) Ｃｄ３特異的結合ドメインによって引き起こされる潜在的有害事象を緩和するための抗白血球接着
JP7523084B2 (ja) 抗ガレクチン－９抗体及びその使用
US11579142B2 (en) Dosage regimen for administering a CD19xCD3 bispecific antibody to patients at risk for potential adverse effects
JP6709215B2 (ja) 抗ｔｉｍ−３抗体
US20220275091A1 (en) Combination of tim-4 antagonist and pd-1 antagonist and methods of use
CA2959821C (en) Compositions and methods for inducing phagocytosis of MHC class I positive cells and for overcoming resistance to anti-CD47 agents/SIRPA
DK2493503T3 (en) DOSAGE SCHEDULE FOR THE ADMINISTRATION OF A CD19xCD3 bispecific antibody
JP2019517773A (ja) 抗ｌａｇ−３抗体
JP2018508475A (ja) 抗ｐｄ−ｌ１抗体
KR20220005627A (ko) 면역반응의 조절을 위한 방법 및 항체
CN111655286A (zh) 作为免疫调节剂的cd96结合剂
EP3774903A1 (en) Anti-cd27 antibodies and uses thereof
EP3116910A1 (en) Combination treatment for multiple sclerosis
RU2855512C2 (ru) Антитела против siglec-15 и способы их применения
TW202448504A (zh) Btn3a活化抗體及免疫檢查點抑制劑之組合
CN118742323A (zh) Kir3dl3抑制剂和免疫细胞激活剂
HK40130000A (en) Anti-galectin-9 antibodies and uses thereof
HK1190642B (en) Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects
HK1190642A (en) Dosage regimen for administering a cd19xcd3 bispecific antibody to patients at risk for potential adverse effects

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160202

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20170124

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20170830

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20171122

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180122

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20180216

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20180516

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20180814

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20181011

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20190130

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190528

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A821

Effective date: 20190529

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190621

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20190624

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20190729

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20190731

R150 Certificate of patent or registration of utility model

Ref document number: 6567425

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250